“…In a prospective, non-randomized, single-center study, Zagidullin et al demonstrated that, in patients with STEMI, sST2 had a better prognostic value for cardiovascular (CV) mortality at two years in association with NT-proBNP and pentraxin-3 (Ptx-3), rather than alone, or in combination with only one other value [ 172 ]. Additionally, a recently meta-analysis that aimed to evaluate the diagnostic value of sST2 in CV diseases suggested that its prognostic value is often a negative one, and it can predict the LV function after AMI; however, further investigations are required [ 173 ]. A series of studies assessed the cut-off value of sST2 in patients with STEMI undergoing primary PCI for a variety of MACEs at 1 year follow-up (such as impaired myocardial revascularization, HF, all-cause death, non-fatal myocardial infarction and non-fatal stroke), finding mean variation levels greater than 75.8 ng/mL, 58.3 ng/mL or even 2.003 ng/mL (for the revascularization part) [ 173 , 174 , 175 , 176 ].…”